SUYASH GUPTA

H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 H.R. 8324, Great American Healthcare Plan, including provisions related to expansion of Health Savings Accounts (HSAs) S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements, RIN number: 0910-AJ14; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Notice, List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act (91 Fed. Reg. 23,431-23,444, May 1, 2026) Proposed Rule, Electronic Disclosure by Group Health Plans Under ERISA (91 Fed. Reg. 46,602-46,632, July 23, 2026) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates, and legislative proposals to expand government-run healthcare; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; Executive Order 14420, Delivering Gold Standard Childhood Vaccine Recommendations for Americans, including maintaining evidence-based vaccine review through the CDC Advisory Committee on Immunization Practices (ACIP) and the feasibility of separating combination vaccines such as MMR; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care, including a consistent national framework, regulatory clarity for clinical AI, responsible governance, interagency and public-private coordination, and health data interoperability; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements; Food and Drug Administration (FDA) proposal not to include semaglutide, tirzepatide, or liraglutide on the 503B Bulks List, and issues related to pharmaceutical innovation incentives, fair competition, and domestic pharmaceutical manufacturing and supply chain resilience; policies related to prior authorization, HIPAA reform, and health information interoperability; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater regulatory convergence and harmonization; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Notice, List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act (91 Fed. Reg. 23,431-23,444, May 1, 2026) Proposed Rule, Electronic Disclosure by Group Health Plans Under ERISA (91 Fed. Reg. 46,602-46,632, July 23, 2026) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates, and legislative proposals to expand government-run healthcare; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; Executive Order 14420, Delivering Gold Standard Childhood Vaccine Recommendations for Americans, including maintaining evidence-based vaccine review through the CDC Advisory Committee on Immunization Practices (ACIP) and the feasibility of separating combination vaccines such as MMR; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care, including a consistent national framework, regulatory clarity for clinical AI, responsible governance, interagency and public-private coordination, and health data interoperability; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements; Food and Drug Administration (FDA) proposal not to include semaglutide, tirzepatide, or liraglutide on the 503B Bulks List, and issues related to pharmaceutical innovation incentives, fair competition, and domestic pharmaceutical manufacturing and supply chain resilience; policies related to prior authorization, HIPAA reform, and health information interoperability; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater regulatory convergence and harmonization; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 H.R. 8324, Great American Healthcare Plan, including provisions related to expansion of Health Savings Accounts (HSAs) S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements, RIN number: 0910-AJ14; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 H.R. 8324, Great American Healthcare Plan, including provisions related to expansion of Health Savings Accounts (HSAs) S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements, RIN number: 0910-AJ14; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 H.R. 8324, Great American Healthcare Plan, including provisions related to expansion of Health Savings Accounts (HSAs) S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements, RIN number: 0910-AJ14; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Notice, List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act (91 Fed. Reg. 23,431-23,444, May 1, 2026) Proposed Rule, Electronic Disclosure by Group Health Plans Under ERISA (91 Fed. Reg. 46,602-46,632, July 23, 2026) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates, and legislative proposals to expand government-run healthcare; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; Executive Order 14420, Delivering Gold Standard Childhood Vaccine Recommendations for Americans, including maintaining evidence-based vaccine review through the CDC Advisory Committee on Immunization Practices (ACIP) and the feasibility of separating combination vaccines such as MMR; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care, including a consistent national framework, regulatory clarity for clinical AI, responsible governance, interagency and public-private coordination, and health data interoperability; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements; Food and Drug Administration (FDA) proposal not to include semaglutide, tirzepatide, or liraglutide on the 503B Bulks List, and issues related to pharmaceutical innovation incentives, fair competition, and domestic pharmaceutical manufacturing and supply chain resilience; policies related to prior authorization, HIPAA reform, and health information interoperability; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater regulatory convergence and harmonization; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 H.R. 8324, Great American Healthcare Plan, including provisions related to expansion of Health Savings Accounts (HSAs) S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements, RIN number: 0910-AJ14; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 2528/S. 1847, Association Health Plans Act H.R. 5463, Choice Arrangement Act of 2025 S. 2875, Custom Health Option and Individual Care Expense (CHOICE) Act Notice, List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act (91 Fed. Reg. 23,431-23,444, May 1, 2026) Proposed Rule, Electronic Disclosure by Group Health Plans Under ERISA (91 Fed. Reg. 46,602-46,632, July 23, 2026) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates, and legislative proposals to expand government-run healthcare; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; legislative proposals to tax employer-provided health care coverage; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; Executive Order 14420, Delivering Gold Standard Childhood Vaccine Recommendations for Americans, including maintaining evidence-based vaccine review through the CDC Advisory Committee on Immunization Practices (ACIP) and the feasibility of separating combination vaccines such as MMR; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care, including a consistent national framework, regulatory clarity for clinical AI, responsible governance, interagency and public-private coordination, and health data interoperability; Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) pending rulemaking to rescind the "adequate provision" standard for direct-to-consumer (DTC) prescription drug advertisements; Food and Drug Administration (FDA) proposal not to include semaglutide, tirzepatide, or liraglutide on the 503B Bulks List, and issues related to pharmaceutical innovation incentives, fair competition, and domestic pharmaceutical manufacturing and supply chain resilience; policies related to prior authorization, HIPAA reform, and health information interoperability; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater regulatory convergence and harmonization; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including PBM transparency provisions Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); health reimbursement arrangements and other account-based group health plans; mental health parity; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Executive Order 14297, Delivering Most‑Favored‑Nation Prescription Drug Pricing to American Patients; ERISA preemption protections including information on constructive changes/modifications to ERISA; TRUMP AMERICA AI Act and AI proposals impacting health care; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the WHO; support for necessary market conditions to incentivize health sector investment, grow markets, sustain business operations, and improve access to health commodities globally; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)

H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)

H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)

H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2028/S. 1847, the Association Health Plans Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 763, Telehealth Expansion Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Request for Information, Ultra Processed Foods (90 Fed. Reg. 35,305-35,309, July 25, 2025) Request for Information, NIH Artificial Intelligence Strategy (Response to NIH RFI NOT-OD-25-117), July 15, 2025 Request for Information, Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again (90 Fed. Reg. 20,478-20,481, July 14, 2025) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credit expiration; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 1, One Big Beautiful Bill Act H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 919, Chronic Disease Flexible Coverage Act H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528, Association Health Plans Act H.R. 2571, Self-Insurance Protection Act S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024); Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)